AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models

Cancer Letters

Volumn 358, Issue 1, 2015, Pages 85-91

  Kim, Eun Young ^a   Kim, Arum ^a   Kim, Se Kyu ^a   Chang, Yoon Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bcl2 like 11 (BIM); Cisplatin; KRAS; MEK1 2 inhibitor; NSCLC

Indexed keywords

CISPLATIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN BCL 2; SELUMETINIB; SHORT HAIRPIN RNA; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MOUSE; MOUSE STRAIN; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALIA; MUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84921277877     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.041     Document Type: Article

References (46)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin 2012, 62:10-29.
2. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med 2006, 355:2542-2550.
3. Akaboshi M., Kawai K., Ujeno Y., Takada S., Miyahara T. Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans-diamminedichloroplatinums(II). Jpn. J. Cancer Res 1994, 85:106-111.
4. Brozovic A., Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007, 251:1-16.
5. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
6. Zeng H.H., Wang K., Wang B., Zhang Y. Studies on the thermokinetic characterisation of actin polymerization and the effect of cisplatin. Int. J. Biol. Macromol 1996, 18:161-166.
7. Tulub A.A., Stefanov V.E. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int. J. Biol. Macromol 2001, 28:191-198.
8. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
9. Wang X., Martindale J.L., Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem 2000, 275:39435-39443.
10. Choi B.K., Choi C.H., Oh H.L., Kim Y.K. Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicology 2004, 25:915-924.
11. Urso L., Muscella A., Calabriso N., Ciccarese A., Fanizzi F.P., Migoni D., et al. Differential functions of PKC-delta and PKC-zeta in cisplatin response of normal and transformed thyroid cells. Biochem. Biophys. Res. Commun 2005, 337:297-305.
12. Woessmann W., Chen X., Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol 2002, 50:397-404.
13. Kim M., Yan Y., Kortum R.L., Stoeger S.M., Sgagias M.K., Lee K., et al. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. Cancer Res 2005, 65:3986-3992.
14. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev 2004, 68:320-344.
15. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.
16. Billard C. BH3 mimetics: status of the field and new developments. Mol. Cancer Ther 2013, 12:1691-1700.
17. Wang J., Zhou J.Y., Wu G.S. Bim protein degradation contributes to cisplatin resistance. J. Biol. Chem 2011, 286:22384-22392.
18. Strasser A., Cory S., Adams J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011, 30:3667-3683.
19. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol 2008, 26:2139-2146.
20. Rinehart J., Adjei A.A., LoRusso P.M., Waterhouse D., Hecht J.R., Natale R.B., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol 2004, 22:4456-4462.
21. Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14:38-47.
22. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev 2006, 58:621-681.
23. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001, 15:3243-3248.
24. Park S.A., Park H.J., Lee B.I., Ahn Y.H., Kim S.U., Choi K.S. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res. Mol. Brain Res 2001, 93:18-26.
25. Arany I., Megyesi J.K., Kaneto H., Price P.M., Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol 2004, 287:F543-F549.
26. Cui W., Yazlovitskaya E.M., Mayo M.S., Pelling J.C., Persons D.L. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol. Carcinog 2000, 29:219-228.
27. Hayakawa J., Ohmichi M., Kurachi H., Ikegami H., Kimura A., Matsuoka T., et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem 1999, 274:31648-31654.
28. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res 1999, 5:1007-1014.
29. de Jonge M.J., Verweij J., de Bruijn P., Brouwer E., Mathijssen R.H., van Alphen R.J., et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J. Clin. Oncol 2000, 18:195-203.
30. Urien S., Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br. J. Clin. Pharmacol 2004, 57:756-763.
31. Pritchard J.R., Bruno P.M., Gilbert L.A., Capron K.L., Lauffenburger D.A., Hemann M.T. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E170-E179.
32. Blanchard J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem 1996, 65:215-239.
33. Han J.Y., Hong E.K., Choi B.G., Park J.N., Kim K.W., Kang J.H., et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med. Oncol 2003, 20:355-362.
34. Erovic B.M., Pelzmann M., Grasl M., Pammer J., Kornek G., Brannath W., et al. Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Clin. Cancer Res 2005, 11:8632-8636.
35. Williams J., Lucas P.C., Griffith K.A., Choi M., Fogoros S., Hu Y.Y., et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol 2005, 96:287-295.
36. Michaud W.A., Nichols A.C., Mroz E.A., Faquin W.C., Clark J.R., Begum S., et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin. Cancer Res 2009, 15:1645-1654.
37. Luciano F., Jacquel A., Colosetti P., Herrant M., Cagnol S., Pages G., et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003, 22:6785-6793.
38. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med 2006, 355:983-991.
39. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med 2007, 356:800-808.
40. Kirschner K., Melton D.W. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 2010, 30:3223-3232.
41. Yu J.J., Thornton K., Guo Y., Kotz H., Reed E. An ERCC1 splicing variant involving the 5'-UTR of the mRNA may have a transcriptional modulatory function. Oncogene 2001, 20:7694-7698.
42. Chen H.Y., Shao C.J., Chen F.R., Kwan A.L., Chen Z.P. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 2010, 126:1944-1954.
43. Li Q., Gardner K., Zhang L., Tsang B., Bostick-Bruton F., Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J. Biol. Chem 1998, 273:23419-23425.
44. Andrieux L.O., Fautrel A., Bessard A., Guillouzo A., Baffet G., Langouet S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007, 67:2114-2123.
45. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
46. Denton C.L., Gustafson D.L. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother. Pharmacol 2011, 67:349-360.